This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
11/4/2025
Operator
Conference Operator
Good afternoon and thank you for standing by. Welcome to Celeno Therapeutics' third quarter, 2025 Financial and Operating Results Conference Call and Webcast. Currently, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. As a reminder, today's webcast is being recorded. I would now like to introduce Brian Ritchie of Lifesite Advisors. Please go ahead.
Brian Ritchie
Partner, Lifesite Advisors
Thank you.
Brian Ritchie
Partner, Lifesite Advisors
Good afternoon, everyone, and thank you for joining us to discuss Celeno Therapeutics' third quarter 2025 financial and operating results. Please note, we will be making certain forward-looking statements today. We refer you to Celeno's SEC filings for a discussion of the risks that may cause actual results to differ from the forward-looking statements. On the call with me today for Celeno are Anish Bhatnagar, Solano's Chairman and Chief Executive Officer, Meredith Manning, Solano's Chief Commercial Officer, and Jim McInnis, Solano's Chief Financial Officer. With that, I will now turn the call over to Anish.
You're reading a preview of the SLNO Q3 2025 earnings call.
Free account.
Disclaimer